<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01597726</url>
  </required_header>
  <id_info>
    <org_study_id>32020</org_study_id>
    <nct_id>NCT01597726</nct_id>
  </id_info>
  <brief_title>Cervical Priming Before Dilation &amp; Evacuation</brief_title>
  <official_title>Cervical Priming Before Dilation &amp; Evacuation: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ibis Reproductive Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Cape Town</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tygerberg Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Safe Abortion Action Fund of the International Planned Parenthood Federation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Society of Family Planning</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ibis Reproductive Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy of buccal misoprostol cervical priming
      to laminaria priming among women undergoing D&amp;E at 13-20 weeks gestation in the Western Cape
      Province, South Africa
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      As misoprostol is increasingly being used for cervical preparation, concerns about its use
      and about the proportion of women expelling the fetus prior to the D&amp;E and other side effects
      mean that rigorous data on possible advantages of osmotic dilators are needed. To address
      this gap in the literature, we propose to perform an RCT comparing two methods of cervical
      preparation prior to D&amp;E:

        1. Misoprostol 400 mcg administered buccally approximately 3-6 hours prior to D&amp;E, repeated
           once 3 hours after the first dose (a modified version of the current protocol)

        2. Laminaria tents inserted into the cervix 18 to 24 hours prior to D&amp;E
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of women with fetal expulsion prior to dilation and evacuation</measure>
    <time_frame>Prior to D&amp;E procedure</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of women requiring additional dilation (manual or pharmacologic)</measure>
    <time_frame>At time of D&amp;E procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of dilation and evacuation procedure</measure>
    <time_frame>End of D&amp;E procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of major complications</measure>
    <time_frame>Recorded at TOP visit and/or follow-up visit (target 7 days after procedure)</time_frame>
    <description>Major complications to include:
Death
Admission to the ward after the procedure
Readmission after discharge
Abdominal surgical procedure
Suspected uterine perforation
Seizure
Hemorrhage requiring transfusion
Loss to follow-up after placement of laminaria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Minor Complications</measure>
    <time_frame>Recorded at TOP visit and/or follow-up visit (target 7 days after procedure)</time_frame>
    <description>Minor complications to include:
Hemorrhage not requiring transfusion
Infection requiring outpatient treatment
Trauma to cervix or vagina
Transfer to another facility to complete the procedure
Need for repeat surgical evacuation of the uterus</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">159</enrollment>
  <condition>Abortion, Induced</condition>
  <arm_group>
    <arm_group_label>Misoprostol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Laminaria</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Misoprostol</intervention_name>
    <description>Misoprostol 400 mcg administered buccally approximately 3-6 hours prior to D&amp;E, repeated once 3 hours after the first dose if needed</description>
    <arm_group_label>Misoprostol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Laminaria</intervention_name>
    <description>Laminaria tents inserted into the cervix 18 to 24 hours prior to D&amp;E</description>
    <arm_group_label>Laminaria</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Woman seeking TOP between 13 and 20 weeks gestation as determined by ultrasound

          -  Age 18 or greater

          -  Willingness to participate in randomized study

          -  Fluency in English, Afrikaans or Xhosa

          -  Ability to give informed consent

          -  Staying within one hour travel time of Tygerberg Hospital for the night prior to the
             D&amp;E

          -  Ability to be contacted by telephone

        Exclusion Criteria:

          -  Active cervicitis

          -  Multiple gestation

          -  Fetal demise confirmed by ultrasound examination

          -  History of bleeding disorder or current anticoagulation therapy

          -  Allergy to misoprostol

          -  Currently breastfeeding and unwilling or unable to temporarily discard milk

          -  More than one prior cesarean delivery
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Judy Kluge, MBChB</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tygerberg Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tygerberg Hospital</name>
      <address>
        <city>Cape Town</city>
        <zip>7505</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <link>
    <url>http://www.ibisreproductivehealth.org/</url>
    <description>Click here to visit the Ibis Reproductive Health website</description>
  </link>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 10, 2012</study_first_submitted>
  <study_first_submitted_qc>May 11, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 14, 2012</study_first_posted>
  <last_update_submitted>November 6, 2013</last_update_submitted>
  <last_update_submitted_qc>November 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 7, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Abortion, Induced</keyword>
  <keyword>Laminaria</keyword>
  <keyword>Misoprostol</keyword>
  <keyword>Pregnancy Trimester, Second</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Misoprostol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

